Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

L Hillebrand, XJ Liang, RAM Serafim… - Journal of Medicinal …, 2024 - ACS Publications
Covalent inhibitors and other types of covalent modalities have seen a revival in the past two
decades, with a variety of new targeted covalent drugs having been approved in recent …

Characterization of thermostable carboxypeptidase from high-altitude hot spring metagenome

AK Wani, C Chopra, MA Ansari, MA Dar… - International Journal of …, 2024 - Elsevier
This study explored the metagenome of the Pir Panjal Hot Spring (PPHS) to identify
thermostable hydrolases. The carboxypeptidase (CarP) gene was successfully amplified …

Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity

GR Velma, Z Shen, C Holberg, J Fu… - Journal of Medicinal …, 2024 - ACS Publications
The SARS-CoV-2 papain-like protease (PLpro), essential for viral processing and immune
response disruption, is a promising target for treating acute infection of SARS-CoV-2. To …

Covalent Inhibitors of MAP Kinases

SK De - Drug Design and Discovery: Inhibitors of Mitogen …, 2024 - Springer
Several covalent inhibitors such as aspirin, Penicillin G, and Omeperazole have been used
for decades. Covalent inhibitors form a covalent bond with a specific target protein and …

Drug Design and Discovery

SK De - Springer
After proteases, the protein kinase family is the second largest enzyme family and the fifth
largest gene family in humans. Protein kinases are the second largest group of drug targets …

Discovery of Small Molecule Drugs against Crucial Proteins, Papain-like Protease (PLpro) and Non-structural protein 15 (Nsp15), from SARS-CoV-2 virus

T Bajaj - 2024 - search.proquest.com
The emergence and rapid spread of the severe acute respiratory syndrome coronavirus 2,
SARS-CoV-2 (SCoV-2) caused catastrophic levels of morbidity in the world and presented …